This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why Is Sarepta Therapeutics (SRPT) Down 1.9% Since Last Earnings Report?
by Zacks Equity Research
Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Halozyme Therapeutics (HALO) Up 14.8% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Halozyme Therapeutics (HALO) is a Top Momentum Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Madrigal (MDGL) Tops on Q2 Earnings, NASH Drug Drives Top Line
by Zacks Equity Research
Madrigal (MDGL) posts better than expected second-quarter numbers. It adds nearly $15 million from sales of the first-ever NASH drug Rezdiffra, which is encouraging for a drug launched in April 2024.
Halozyme's (HALO) Q2 Earnings & Sales Top Estimates, Stock Up
by Zacks Equity Research
Halozyme (HALO) reports better-than-expected second-quarter 2024 results. The company maintains revenue guidance for 2024. Stock rises in after-hours trading.
Zacks.com featured highlights include Halozyme Therapeutics, Leidos Holdings, Atmos Energy and Addus HomeCare
by Zacks Equity Research
Halozyme Therapeutics, Leidos Holdings, Atmos Energy and Addus HomeCare have been highlighted in this Screen of The Week article.
Compared to Estimates, Halozyme Therapeutics (HALO) Q2 Earnings: A Look at Key Metrics
by Zacks Equity Research
Although the revenue and EPS for Halozyme Therapeutics (HALO) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Halozyme Therapeutics (HALO) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of 16.67% and 9.69%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
4 Stocks That Flaunt an Impressive Interest Coverage Ratio
by Sumit Singh
A company that is capable of generating earnings well above its interest expense can withstand financial hardship. HALO, LDOS, ATO & ADUS are sound enough to meet financial obligations.
Theravance (TBPH) Q2 Loss Wider Than Expected, Revenues Rise Y/Y
by Zacks Equity Research
Theravance (TBPH) misses second-quarter estimates on both fronts. Increased collaboration revenues from Viatris drive year-over-year top-line performance.
CRISPR Therapeutics (CRSP) Q2 Loss Wider Than Expected
by Zacks Equity Research
CRISPR Therapeutics (CRSP) incurs a wider-than-expected loss in the second quarter of 2024. The commercial launch of CRISPR-based gene therapy, Casgevy, is progressing well.
BioMarin (BMRN) Q2 Earnings & Sales Top Estimates, Ups '24 View
by Zacks Equity Research
BioMarin (BMRN) posts better-than-expected second quarter earnings. It also raises its revenue and earnings guidance for full-year 2024.
Curious about Halozyme Therapeutics (HALO) Q2 Performance? Explore Wall Street Estimates for Key Metrics
by Zacks Equity Research
Beyond analysts' top -and-bottom-line estimates for Halozyme Therapeutics (HALO), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2024.
Bausch Health (BHC) Q2 Earnings In Line, Xifaxan Boosts Sales
by Zacks Equity Research
Bausch Health's (BHC) second-quarter adjusted earnings meet estimates while sales top the same, fueled by growth in Xifaxan sales.
Blueprint Medicines (BPMC) Down Despite Q2 Earnings Beat
by Zacks Equity Research
Blueprint Medicines' (BPMC) earnings and revenues surpass estimates in the second quarter of 2024. The company raises its product revenue guidance for 2024. Stock declines.
AGIO Q2 Earnings Lag, Stock Down on Missing Pediatric Study Goal
by Zacks Equity Research
Agios' (AGIO) second-quarter 2024 numbers miss estimates. Its sole-marketed drug fails to meet the primary endpoint of a late-stage label expansion study in pediatric patients with PK deficiency.
Perrigo (PRGO) Beats on Q2 Earnings, Lags Sales, Cuts View
by Zacks Equity Research
Perrigo (PRGO) reports mixed second-quarter 2024 results. It cuts total net sales forecasts primarily due to expected lower distribution in U.S. store brand in second-half 2024.
Puma Biotechnology's (PBYI) Q2 Loss Narrower Than Expected
by Zacks Equity Research
Puma Biotechnology (PBYI) beats second-quarter estimates for both the top and the bottom line.
Vertex (VRTX) Q2 Loss Wider Than Expected, '24 Sales View Raised
by Zacks Equity Research
Vertex (VRTX) incurs a wider-than-expected loss in the second quarter while sales come in line with estimates. Vertex raises its full-year product revenue guidance.
Amarin (AMRN) Stock Down Despite Q2 Earnings & Revenues Beat
by Zacks Equity Research
Amarin's (AMRN) second-quarter 2024 earnings and revenues beat estimates. Vascepa's sales in the United States decline year over year. Stock down.
Moderna (MRNA) Q2 Earnings Beat, Stock Down on Guidance Slash
by Zacks Equity Research
Moderna (MRNA) beats expectations for earnings and sales. Management cuts sales guidance by $0.5-$1.0 billion on concerns about competition for its marketed products and low sales in the EU.
JAZZ Tops Q2 Earnings & Sales Estimates, Revises '24 View
by Zacks Equity Research
Jazz's (JAZZ) reports better-than-expected second quarter results. While it revises its guidance for 2024, it withdraws the financial guidance issued as part of the Vision 2025 plan.